




Physiological Basics, and Clinical Implications
Grzegorz M. Kubiak 1 , Agnieszka Ciarka 2, Monika Biniecka 3 and Piotr Ceranowicz 4,*
1 Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart
Diseases, Medical University of Silesia, 41-800 Zabrze, Poland
2 Department of Cardiovascular Diseases, University Hospitals Leuven, University of Leuven, Herestraat 49,
Leuven 3000, Belgium
3 KardioMed Silesia, M. Curie-Skłodowskiej 10C, 41-800 Zabrze, Poland
4 Department of Physiology, Faculty of Medicine, Jagiellonian University Medical College,
31-008 Kraków, Poland
* Correspondence: piotr.ceranowicz@uj.edu.pl
Received: 5 July 2019; Accepted: 25 August 2019; Published: 28 August 2019


Abstract: The idea of right heart catheterization (RHC) grew in the milieu of modern thinking about
the cardiovascular system, influenced by the experiments of William Harvey, which were inspired by
the treatises of Greek philosophers like Aristotle and Gallen, who made significant contributions to the
subject. RHC was first discovered in the eighteenth century by William Hale and was subsequently
systematically improved by outstanding experiments in the field of physiology, led by Cournand and
Dickinson Richards, which finally resulted in the implementation of pulmonary artery catheters (PAC)
into clinical practice by Jeremy Swan and William Ganz in the early 1970s. Despite its premature
euphoric reception, some further analysis seemed not to share the early enthusiasm as far as the safety
and effectiveness issues were concerned. Nonetheless, RHC kept its significant role in the diagnosis,
prognostic evaluation, and decision-making of pulmonary hypertension and heart failure patients.
Its role in the treatment of end-stage heart failure seems not to be fully understood, although it is
promising. PAC-guided optimization of the treatment of patients with ventricular assist devices and
its beneficial introduction into clinical practice remains a challenge for the near future.
Keywords: right heart catheterization; pulmonary hypertension; heart failure; diagnosis; prognostic
evaluation; clinical implications
1. Introduction
1.1. Aim of the Review
To elucidate the state of the art of right heart catheterization, focusing on the background of the
initial experiments and its physiological meaning, which leads to its implementation in clinical practice.
To indicate potential directions for future research.
1.2. From Greek Philosophy into Modern Understanding
Right heart catheterization (RHC) has emerged as an invasive procedure with a potent role
among the current armory of clinical diagnostic tools, including computed tomography (CT), magnetic
resonance imaging (MRI), and genetical immunoassays sampling [1,2]. The birth of this technique is
strictly associated with the genial English physiologist and physician William Harvey (1578–1657),
who actually proposed a theoretical model of the functioning of an animal circulatory system, which
he unveiled in the work entitled Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus
and published in 1628 in Frankfurt [3].
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The work, containing 17 chapters within 72 pages, irretrievably changed the modern understanding
of the blood circulation. It is important to keep in mind that Galen was the first person to make
extraordinary contributions to the concepts of physiology and medicine that turned out to be widely
accepted paradigms. He believed that the circulatory system consisted of two separated parts:
venous, originating from the liver, and arterial, originating from the heart. The idea of two separate,
unidirectional systems of distribution rather than a unified system of circulation remained unchallenged
for many centuries. Harvey, although heavily influenced by his potent predecessor, unwillingly found
himself in the position of a revolutionary antagonizer. Harvey’s way of thinking and analyzing
different phenomena was heavily influenced by another ancient Greek philosopher, Aristotle [4,5].
The Aristotelian way of thinking would be to engage not only rigorous mathematical calculations but
also analogies to the natural phenomena covered by physics, biology, and other empirical sciences.
“De motu cordis” was released in Europe during the Thirty Years’ War, described as one of
the most destructive and violent periods in human history. This era was characterized by different
political, religious, and cultural movements (the Reformation, Counter-reformation, and forming of
the Anglican Church). During these times of overwhelming crime, plagues, and the rising wave of
inquisition, the signs of independent thinking, especially when based on evidence and experiments,
were unwanted and considered dangerous [6,7].
1.3. Pioneers of Right Heart Catheterization
As time passed, further attempts to experimentally evaluate the circulatory system were made.
In 1711, Stephen Hale reported the measurement of cardiac output (CO) with the use of brass
pipes introduced into equine veins and arteries [8–11]. The technical aspects of these examinations
were further improved by Claude Bernard, who challenged the pulmonary combustion model
of circulation, claiming that the blood temperature varies significantly between the systemic and
pulmonary circulatory system [12]. Since his previous attempts to encounter surgical techniques in the
temperature measurement appeared to be inaccurate, Bernard developed the technique of exposing
the jugular vein and carotid artery of a horse in order to perform the measurements above. Bernard
proved the technical feasibility of those examinations, which were continued by another two French
physiologists, Baptiste Chauveau and Étienne Marey [13–15]. The collaboration of these has been
linked to the virtual beginning of intracardiac pressure recordings.
The innovative dual-lumen catheter device was designed to simultaneously assess the intracardiac
pressures of the left ventricle and the aorta, as well as the atrium and the right ventricle.
These experiments discovered the so far unreported phenomena of ventricular pressure curves,
isometric phase of ventricular contraction, interventricular synchrony, and the chronology of valve
closing. It is worth noting that Marey was also renowned as a pioneer of electrocardiography,
with significant contributions in the field made by the discovery of the refractory period in 1875 and
the first recording of electrocardiogram with the use of capillary electrometer in 1876 [16].
Remarkably, it was nearly three decades before Willem Einthoven reported his invention,
which was about to revolutionize the modern diagnosis and treatment of cardiovascular disorders.
In his late years, Marey, being somehow possessed by the idea of a general visualization of the
motion of different species present in the environment, turned his professional activity towards
chronophotography, which he documented in books entitled Le mouvement and Le vol des oiseaux [17].
1.4. Nobel Prize for the Famous Three
German scientists Fritz Bleichroeder, Ernst Unger, and W. Loeb continued the pathway of right
heart catheterization in animals, and performed self-experiments in that field; however, these were
scarcely documented [18]. A breakthrough came when a recently graduated doctor Werner Forssmann
performed the first in-vivo catheterization of his own heart, which took place in Eberswalde in
1929 [19–24]. This experiment was an act of bravery which took the human cardiac catheterization
from theory into practice in a short period of time. Forssmann’s attitude towards the National Socialist
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German Workers’ Party (NSDAP) arose from the phase of an early euphoria into the late deception
and was basically indifferent from the typical attitude of his fellow countrymen [25].
The denazification process, to which he had been submitted in the late 1940s, did not alter his
recognition in the area of right catheterization, for which he was awarded the Nobel Prize in 1956,
along with Doctors André Cournand and Dickinson Richards. Remarkably, Doctors Cournand and
Richards, during their work at the Department of Physiology of the Bellevue Hospital in New York,
made an extraordinary contribution to the refinement of the antecedents techniques; they were the first
to report a reliable measurement of CO using the Fick principle [26].
1.5. Jeremy Swan and William Ganz—Catheterization in Clinical Practice
Moreover, they understood the phenomenon of oxygen debt in the setting of “clinical shock”,
which they managed to treat successfully with the implementation of a human serum albumin [27].
These observations set the stage for future scientific research in the field of different kinds of shock, their
risk stratification and management [28,29]. Interestingly, Cournand positively verified the usefulness
of a ballistocardiogram and its correlation with the results of invasive measurement of CO performed
using the Fick principle [30]. Having proven that the catheter might be uneventfully left in the right
heart cavities for a prolonged period, exceeding twenty-four hours, some further improvements were
made, which eventually evolved into the discovery of the pulmonary capillary/artery wedge pressure
(PCWP/PAWP).
Its monitoring, first demonstrated by Hellems and co-workers, was a fairly safe technique
of estimating left atrial pressure in the absence of mitral regurgitation [31]. Remarkably, another
innovation was associated with the introduction of a balloon at the end of the tip, whose presence
facilitated migration with the blood flow [32,33]. Another improvement was associated with the
utilization of the thermodilution method to precisely assess CO. Needless to say, it added important
information that, along with the modifications above, appears safe and reliable [34,35]. To see the
milestones of RHC, please refer to Figure 1.
1.6. Technique of the Measurement and Basic Definitions
The preferred access point is the internal jugular vein. Its patency and anatomical
conditions are reassured during an ultrasound examination, which is believed to reduce access
site complications [36–39]. The currently used Seldinger technique is based on the principle of a
guiding wire that enters into the vessel lumen. After an anatomical evaluation of a correct position,
a special, dedicated sheath with a valve is inserted into the lumen, enabling easy access into the internal
jugular vein and the subsequent structures [40–43]. A Swan-Ganz (S-G) catheter, basically not different
from the prototype used by its inventors in 1970, is inserted via the internal jugular vein into the
right atrium, ventricle, and pulmonary arteries. In some cases, RHC might be technically demanding,
particularly in individuals with severely dilated right ventricle (RV) due to pulmonary hypertension,
severe tricuspid regurgitation (TR), or other obstacles located in the right heart, like pacemaker leads
or artificial valves. In these cases, the use of fluoroscopic guidance or even the angioplasty wire in
order to acquire an adequate PAWP may be beneficial. An unreliable PAWP value may be verified by a
direct left ventricular end-diastolic pressure (LVEDP) measurement via the arterial access [44]. Several
potential pitfalls may occur during RHC. It should be underlined that PAWP is vulnerable to errors in
parameter of key importance in the diagnosis of pulmonary hypertension (PH). It might be either over-
or, more often, under-wedged, which may lead to a misdiagnosis and, consequently, inappropriate
treatment [45]. Since the PAWP is heavily dependent on respiration, it is a subject of debate whether it
should be measured at the end-expiration or averaged during spontaneous breathing [44,45]. It applies
mainly to the patients with respiratory disorders, in whom there is an intrathoracic pressure swing
influencing the intracardiac conditions [45].
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Figure 1. The milestones of right heart catheterization (RHC). 
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recommend performing the zeroing of the transducer at the mid-thoracic line (with the reference 
point defined by the crossing of the frontal plane at the mid-thoracic level, the transverse plane at the 
level of the fourth anterior intercostal space, and the midsagittal plane in a supine patient halfway 
between the anterior sternum and the bed surface [1,46]). It is important to emphasize the role of an 
adequate calibration of the pressure transducer; however, the theoretical and experimental 
background of right ventricle elasticity, along with the associations concerning volumes in different 
clinical states and different species, falls beyond the scope of the current review [47–56]. For research 
purposes, it is recommended to perform a single-beat estimation of the right ventricular end-systolic 
pressure–volume relationship [57–59]. To see the typical pressure curves and values assessed during 
RHC within the physiological states please refer to Figure 2. 
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Table 1. Basic definitions and the range of normal values.
Parameter Abbreviation Normal Value Definitions/Comments
Heart rate HR 60–100 bpm number of beats per minute
Stroke volume SV 60–100 mL/beat the amount of blood pumped by each ventricle of the heartduring contraction
Cardiac output CO 4.0–8.0 L/min volume of blood being pumped within the minute
Body surface area BSA 1.6–1.9 m2 the measured or calculated surface area of a human body
Cardiac index CI 2.5–4.0 L/min/m2 CO/BSA
Central Venous Pressure CVP 2–6 mmHg superior vena cava pressure—might be used to estimatepreload and right atrial pressure
Right atrial pressure RAP 2–6 mmHg usually RAP~CVP
Pulmonary artery pressure
(systolic/diastolic/mean) (s/d/m) PAPs/d/m 15–30/8–15/9–18 mmHg assessed by a Swan-Ganz catheter placed in either RPA or LPA
Pulmonary artery wedge pressure PAWP 6–12 mmHg the inflated balloon of the catheter tip passively transmits thepressure of LA
Transpulmonary gradient TPG ≤12 mm Hg PAPm—PAWPm
Pulmonary vascular resistance PVR <3.125 WU PAPm—PAWPm/CO
Diastolic pulmonary gradient DPG <7 mmHg PAPd—PAWPm
Systemic vascular resistance SVR 10–15 WU SBPm—RAPm/CO
Table legend: SBPm–systemic blood pressure mean, WU–Wood Units.
3. Clinical Practice Implications
3.1. Safety of Right Heart Catheterization—The Evaluation of Clinical Outcomes
Since there existed a vital need to monitor the severely ill patients’ pulmonary artery, catheterization
has been widely introduced into clinical practice, including pediatrics, cardiac surgery, invasive
treatments in different kinds of clinical settings, including a wide variety of shock states originating
from the circulatory and/or septic background [60–68]. The use of this technology, mainly without
appropriate guidance or experience, resulted in few complications, reported thereafter in the form of
case reports [69–75].
These complications had different natures—from relatively mild dissections in the puncture site
to serious ones with systemic clinical implications, like tricuspid valve chord rupture or pulmonary
hemorrhages. Apparently, the learning curve and equipment imperfections could have been blamed
to some extent; however, re-evaluation of this clinical modality of invasive cardiovascular system
assessment, according to the evidence-based medicine, rapidly generated interest in the community of
intensive care practitioners and physicians [76–82].
The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments
(SUPPORT) lead by Connors and co-investigators was the first prospective cohort study designed
to address the issue of pulmonary artery catheter (PAC) effectiveness and costs [76]. PAC (formerly
called the Swan-Ganz catheter) did not have any favorable effect, moreover it significantly raised
the cost of treatment. This work has been succeeded by others, like Wheeler et al., who evaluated
one thousand patients with acute lung injuries and stated that PAC did not have a positive influence
on the course of the management process in comparison to the central venous catheter and should,
therefore, not be used in this clinical condition [77]. Harvey and co-workers did not report any
benefit from the PAC-guided treatment in severely ill patients enrolled within the “PAC-man” trial
in the United Kingdom [78]. Ramsey et al. [82] retrospectively analyzed the outcomes of PAC use
in non-emergent coronary artery bypass graft surgery and stated that not only did PAC not have
any beneficial effect in reducing complications, but it was also associated with a two-fold increase
in mortality, extended the length of hospital stay, and significantly raised the costs [82]. It referred
predominantly to the low volume centers in which the PAC-derived data were apparently inadequately
interpreted. These studies gradually changed the clinical practice in the USA, resulting in a decrease in
PAC use in response, which was reported by Wiener and Ikuta [83,84].
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3.2. The Position of Right Heart Catheterization in the Diagnostic and Management Algorithm of Heart Failure
RHC is currently often used to monitor patients and guide the therapy to optimize filling pressures
and volume overloads. Some centers use it excessively in almost all patients, highlighting the point
that this technique is basically less prone to subjective inter-observer variability. The Evaluation
Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)
(85) investigators assessed the results of using RHC in 433 patients enrolled randomly in either
an interventional or conservative arm. Remarkably, RHC was used intentionally to optimize
pharmacological treatment, not only for those that did not prove any benefit; additionally, it was
associated with a higher risk of adverse events, predominantly PAC infection [85]. Sionis [86] and
co-workers analyzed the data of cardiogenic shock (CS) patients included in the CardShock registry.
Eighty-two of them (37.4%) diagnosed with PAC received goal-oriented therapy consisting of mechanical
ventilation, renal replacement therapy, and mechanical assist devices more often as compared to the
routinely assessed group of patients (p < 0.01). Nevertheless, PAC use was not associated with any
survival benefit within a 30-day observation period, even after propensity score-matching analysis.
Doshi et al. [87] compared the trends in the utilization of PAC between 2005 and 2014 in a total of over
six million of patients with heart failure (HF) with reduced or preserved ejection fraction (HFrEF/HFpEF
respectively). They found that the PAC utilization per 1000 hospitalizations significantly declined
from 2005 to 2010 in both HFrEF and HFpEF. On the contrary, from 2010 to 2014, the use of PAC per
1000 hospitalizations increased in both HFrEF and HFpEF. The temporary decline in risk-adjusted
mortality during the study period for HFrEF and HFpEF is mostly associated with the improvements
in HF therapies. Hernandez [88] and co-authors retrospectively analyzed the trends in PAC utilization
between 2004 and 2014 in a total of 9,431,944 patients admitted with the primary diagnosis of HF
(n = 8,516,528), or who developed CS (n = 915,416) during the index hospitalization. They observed
a decline in the use of PAC in patients with HF, from 8 PAC used per 1000 admissions in 2004 to 6
PAC used per 1000 admissions in 2007. Additionally, there has been a constant rise in PAC use to
12 PAC per 1000 admissions in 2014 (p < 0.001). Interestingly, there has been a gradual decline in
the use of PAC in patients with CS, from 123 PAC used per 1000 admissions in 2004 to 78 PAC per
1000 admissions in 2014 (p < 0.001). Moreover, patients with PAC had increased hospital costs, length
of stay, and mechanical circulatory support use. In patients with HF, PAC use was associated with a
higher mortality. In those with CS, PAC was associated with a lower mortality and lower in-hospital
cardiac arrest; the paradox was also present after propensity score-matching.
Nevertheless, it should be addressed that PAC-guided therapy improved filling pressures and
reduced the rates of atrium/brain natriuretic peptides (ANP/BNP) and patients’ quality of life expressed
by trade-off protocol. Moreover, its use did not have any impact on overall mortality and, last but not
least, its implementation was not assessed in a triage of patients with cardiogenic shock or eligible for
ventricular assist device (VAD)/orthotopic heart transplantation (OHT). On the other hand, Tehrani
et al. proposed a different, team-based therapy for CS on the base of RHC data. This approach
enabled a significant reduction in mortality from 47% in 2016 to 76.6% in 2018 (p < 0.01) [89]. Ma et al.
re-evaluated publicly accessible data on the previously mentioned ESCAPE trial to discriminate the
potential prognostic role of the invasively derived parameters [90]. Their post-hoc analysis revealed that
a group of patients characterized by a single hemodynamic target, defined as PCWP + RAP ≥ 30 mmHg
(congestion index), was associated with poor prognosis and increased relative risk (RR) of death (RR
5.76), death-or-transplantation (DT) (RR 4.92), and death-or-rehospitalization (DR) (RR 1.80) at six
months follow-up. Moreover, this group had 45.3% mortality, 54.7% DT, and 84.9% DR at six months,
contrasting with the cohort of PCWP + RAP < 30 mmHg, which had 8.7% mortality, 13.0% DT, and
58.7% DR at six months. These observations suggest that the PAC-guided treatment of filling pressures
and volume overload in the specific groups of most demanding patients with end-stage heart failure
or after VADs implantations needs to be assessed in randomized controlled trials [91–95], especially
given that the progress in the management of HF through the last decade, including pharmacology and
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technical possibilities, has been promising [96]. To see the recapitulative table with the major studies
and findings, please refer to Table 2, depicted below.
3.3. Position of the RHC in the Diagnostic Algorithm of Pulmonary Hypertension
RHC is currently considered a gold standard in the assessment of PH, which by definition
is associated with the elevation of PAPm above 25 mmHg at rest [1,2,97]. Clinical investigation,
electrocardiogram, chest radiograph, and echocardiography are the first-line examinations in this
entity; however, RHC is obligatory not only to establish the definite diagnosis but also to differentiate
between the subtypes of PH and prognosticate response to treatment and survival rate. Guidelines,
along with the World Health Organization, classify PH into five groups of etiologic entities characterized
by different hemodynamic profiles.
Pre-capillary PH is characterized by PAPm ≥ 25 mmHg, and PAWP ≤ 15 mmHg may occur
in clinical groups 1, 3–5, where groups 2 and 5 in special conditions consist of different forms of
post-capillary PH, which is characterized by PAPm ≥ 25 mmHg and PAWP > 15 mmHg. It can be
further divided into isolated postcapillary PH with DPG (diastolic pressure gradient) < 7 mmHg and/or
PVR ≤ 3 Wood Units (WU), or a combined form of either pre–and post-capillary component with DPG
≥ 7 mmHg and/or PVR > 3 WU. It needs to be underlined that the role of DPG in the diagnosis of PH
has decreased recently, since it is challenging to prove its influence on a patient’s prognosis [98,99].
The physiological characteristics of pulmonary hypertension presented from the clinical point of view
are depicted in Figure 3.
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Table 2. Summary of the most important studies describing the role pulmonary artery catheters.
Author, Reference Number,
and the Year of Publication
Number of Patients and the
Time of Observation Primary Condition Diagnosed/Treated Results and Main Findings
Connors [76], 1996
“SUPPORT” 5735 pts, 180 days
Severe illness.
RHC group versus no RHC group: Acute
respiratory failure:
589 (27%) versus 1200 (34%)
Multiorgan system failure:
1235 (57%) versus 1245 (35%)
Congestive heart failure:
209 (10%) versus 247 (7%)
Other:
151 (7%) versus 859 (24%)
1. Patients with RHC had an increased 30-day mortality (odds ratio, 1.24; 95% confidence interval, 1.03–1.49);
2. The mean cost (25th, 50th, 75th percentiles) per hospital stay was $49 300 ($17,000, $30,500, $56,600) with RHC and $35,700
($11,300, $20,600, $39,200) without RHC;
3. Mean length of stay in the ICU was 14.8 (5, 9, 17) days with RHC and 13.0 (4, 7, 14) days without RHC;
4. Conclusions: After adjustment for treatment selection bias, RHC was associated with increased mortality and increased
utilization of resources.
Wheeler [77], 2006 1000 pts, 60 days Acute lung injury (ALI)
5. Patients randomized into PAC versus CVC guided therapy;
6. The rates of death during the first 60 days before discharge home were similar in the PAC and CVC groups (27.4% and 26.3%,
respectively; p = 0.69);
7. Complications were uncommon and were reported at similar rates in each group: 0.08 ± 0.01 per catheter inserted in the PAC
group and 0.06 ± 0.01 per catheter inserted in the CVC group (p = 0.35);
8. Conclusions: The routine use of PAC in the ALI group of pts is discouraged.
Harvey [78], 2005
“PAC-Man” 1014 pts, 90 days
Acute respiratory failure (13%),
Multiorgan dysfunction (65–66%),
Decompensated heart failure (11%),
Other (10–11%)
9. No difference in hospital mortality between patients managed with or without a PAC (68% (346 of 506) versus 66% (333 of 507),
p = 0.39);
10. No clear evidence of benefit or harm by managing critically ill patients with a PAC;
11. Nearly 10% of pts in the PAC arm suffered from the complications (none of these were fatal).
Ramsey [82], 2004 13,907 pts, 7–8 days Aortocoronary bypass for heartrevascularization—any type
12. The relative risk of in-hospital mortality was 2.10 for the PAC group compared with the patients who did not receive a PAC (95%
confidence interval (CI), 1.40 to 3.14; p < 0.001);
13. The mortality risk was significantly higher in hospitals with the lowest third of PAC use (odds ratio, 3.35; 95% Cl, 1.74 to 6.47;
p < 0.001);
14. Not significantly increased in the highest two thirds of users (odds ratio, 1.62; 95% Cl, 0.99 to 2.66; p = 0.09);
15. Days spent in critical care were similar, although total length of hospital stay was 0.26 days longer in the PAC group (p < 0.001);
16. Hospital costs were $1402 higher in the PAC group.
Binanay [85], 2005
“ESCAPE” 433 pts, 180 days
Severe symptomatic heart failure despite
recommended therapies
17. The use of the PAC did not significantly affect the primary end point of days alive and out of the hospital during the first six
months (133 days versus 135 days; hazard ratio (HR), 1.00 (95% confidence interval (CI), 0.82–1.21); p = 0.99);
18. Mortality (43 patients (10%) versus 38 patients (9%); odds ratio (OR), 1.26 (95% CI, 0.78–2.03); p = 0.35), or the number of days
hospitalized (8.7 versus 8.3; HR, 1.04 (95% CI, 0.86–1.27); p = 0.67);
19. In-hospital adverse events were more common among patients in the PAC group (47 (21.9%) versus 25 (11.5%); p = 0.04);
20. There were no deaths related to PAC use;
21. No difference for in-hospital plus 30-day mortality (10 (4.7%) versus 11 (5.0%); OR, 0.97 (95% CI, 0.38–2.22); p = 0.97);
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Table 2. Cont.
Author, Reference Number,
and the Year of Publication
Number of Patients and the
Time of Observation Primary Condition Diagnosed/Treated Results and Main Findings
Sionis [86], 2019
“CardSchock”
219 pts, 82 (37.4%) received
PAC, 30 days
Patients with cardiogenic shock included
in the CardShock Study
22. Cardiogenic shock patients who managed with a PAC received more frequent treatment with inotropes and vasopressors,
mechanical ventilation, renal replacement therapy, and mechanical assist devices (p < 0.01);
23. Overall 30-day mortality was 36.5%. Pulmonary artery catheter use did not affect mortality even after propensity score matching
analysis (hazard ratio = 1.17 (0.59–2.32), p = 0.66).
Doshi [87], 2018 6,645,363 pts, in hospital staybetween 3–17 days
HFrEF—3,225,529 hospitalizations
HFpEF—3,419,834 hospitalizations
24. Per 1000 hospitalizations, the use of PAC declined from 2005 to 2010 in both HFrEF (12.9 to 7.9, p < 0.001) and HFpEF (12.9 to 5.5,
p < 0.001);
25. From 2010 to 2014, the use of PAC per 1000 hospitalizations increased in both HFrEF (7.9 to 9.7, p < 0.001) and HFpEF (5.5 to 6.7,
p < 0.001);
26. The temporal decline in risk-adjusted mortality during the study period for HFrEF (odds ratio, 3.93 in 2005–2006 to 2.7 in
2013–2014, p < 0.001) and HFpEF (odd ratio, 2.72 in 2005–2006 to 2.62 in 2013–2014, p < 0.001);
27. The length of stay and cost were significantly higher with PAC use in both HFrEF and HFpEF.
Hernandez [88], 2019 9,431,944 pts, in hospital staybetween 2–20 days
HF (n = 8,516,528) index manifestation
CS (n = 915,416) developed during the
index hospitalization
28. Overall, patients with PAC had increased hospital costs, length of stay, and mechanical circulatory support use;
29. In patients with HF, PAC use was associated with higher mortality (9.9% versus 3.3% OR 3.96 p < 0.001);
30. In those with CS, PAC was associated with lower mortality (35.1% versus 39.2% OR 0.91 p < 0.001);
31. And lower in-hospital cardiac arrest (14.9% versus 18.3% OR 0.77 p < 0.001);
32. This paradox persisted after propensity score matching.
Tehrani [89], 2019 204 consecutive pts, 30-daysurvival CS
33. Compared with a 30-day survival of 47% in 2016, the 30-day survival in 2017 and 2018 increased to 57.9% and 76.6%,
respectively (p < 0.01);
34. Independent predictors of 30-day mortality were age ≥ 71 years, diabetes mellitus, dialysis, ≥36 h of vasopressor use at time of
diagnosis, lactate levels ≥ 3.0 mg/dL, CPO < 0.6 W, and PAPi < 1.0 at 24 h after diagnosis and the implementation of therapies;
35. Either 1 or 2 points were assigned to each variable, and a three-category risk score was determined: 0 to 1 (low), 2 to 4
(moderate), and ≥5 (high);
36. Conclusions: A standardized team-based approach may improve CS outcomes;
37. A score incorporating demographic, laboratory, and hemodynamic data may be used to quantify risk and guide clinical
decision-making for all phenotypes of CS.
Table legend: PAC—pulmonary artery catheter, CVC—central venous catheter, ALI—Acute Lung Injury, HR—Hazard ratio, OR—Odds ratio, CI—confidence interval, HFrEF/HFpEF—heart
failure with reduced/preserved ejection fraction, CS—cardiogenic shock, CPO—cardiac power output, PAPi—pulmonary arterial pulsatility index.
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The performance of vasorecactivity testing is recommended in the arterial form of PH, where it
contributes significantly to the choice of the treatment regimen [100]. The encouraged vasoreactive
agent is nitric oxide (NO), with a dose of 10–20 ppm, and the test is interpreted as reactive, whether the
reduction in mean PAP is 10 mmHg or higher. However, the absolute value should be 40 mmHg or
less [1,99]. Patients presenting significant reductions in pulmonary pressures in vasorreactivity testing
during RHC may benefit from calcium channel blockers therapy, although the absolute number of
these cases is quite restricted [101,102].
Some experienced heart centers use the vasoreactivity testing in heart failure scenario associated
with type 2 PH as a part of the integral stratification prior to OHT. Paradoxically, increased PVR above
2.5 WU was associated with unfavorable prognosis only if it was associated with a decrease in systolic
blood pressure below 85 mmHg during vasoreactive testing with sodium nitroprusside [103,104].
These data, although not standardized, sustain the theoretical assumptions that reversibility testing
has the prognostic competence to discriminate the patients prone to developing acute right ventricle
failure after OHT.
4. Conclusions
RHC, although present in experimental physiology and medicine since the beginning of the
seventeenth century, still has safety concerns. These, however, are predominantly related to its
depersonalized, randomly assigned utilization, regardless of its risk-to-benefit ratio to the patients.
RHC is indispensable in PH diagnosis settlement, treatment monitoring, and decision-making.
Moreover, it is imperative prior to OHT to stratify the risk of early post-operative RV failure, which
might be useful in the end-stage heart failure group of patients (including VADs) in the optimization
of pharmacotherapy.
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